The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
 
Miriam Ficial
No Relationships to Disclose
 
Opeyemi Jegede
No Relationships to Disclose
 
Miriam Sant'Angelo
No Relationships to Disclose
 
Sonia Moreno
No Relationships to Disclose
 
David A. Braun
Honoraria - LM Education/Exchange Service
Consulting or Advisory Role - Adept Field Solutions; Blueprint Partnership; Bristol-Myers Squibb; Charles River Associates; Dedham Group; Defined Health; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Megan Wind-Rotolo
Employment - ApotheCom (I); Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jean-Christophe Pignon
Employment - Pyramid Consulting Group
 
Paul J. Catalano
Consulting or Advisory Role - Lilly
 
Maxine Sun
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Gordon J. Freeman
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Adaptimmune (I); Elpiscience (I); Elstar Therapeutics (I); ITeos Therapeutics; Jubilant Therapeutics; Monopteros Therapeutics (I); Monopteros Therapeutics (I); Nextpoint; Origimed; Selecta Biosciences (I); SQZ Biotech (I); Surface Oncology (I); Triursus Therapeutics; Xios Therapeutics
Research Funding - Bristol-Myers Squibb; Ipsen (I); Merck Sharp & Dohme (I); Novartis (I); Quark (I); Roche/Genentech (I); UCB (I)
Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Dako; EMD Serono; Leica Biosystems; Mayo Clinic; Merck; Novartis; Novartis (I); Pfizer (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)
 
Arlene Sharpe
Consulting or Advisory Role - Adaptimmune; BB Biotech Ventures; Bristol-Myers Squibb; Elpiscience; Elstar Therapeutics; igm; ITeos Therapeutics; Jubilant Pharmaceuticals; Monopteros Therapeutics; NextPoint; Origimed; Roche; Selecta Biosciences; SQZ Biotech; Surface Oncology; Triursus Therapeutics; Xios Therapeutics
Research Funding - Bristol-Myers Squibb; Ipsen; Merck; Novartis; Quark; Roche; UCB
Patents, Royalties, Other Intellectual Property - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; DAKO; Leica Biosystems; Mayo Clinic; Merck; Merck Serono; Novartis; Pfizer; Roche
Other Relationship - Journal of Experimental Medicine
(OPTIONAL) Uncompensated Relationships - Novartis
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Catherine J. Wu
Stock and Other Ownership Interests - Neon Therapeutics; Neon Therapeutics (I)
Research Funding - Pharmacyclics
Patents, Royalties, Other Intellectual Property - Neon Therapeutics; Neon Therapeutics (I)
 
Michael B. Atkins
Honoraria - Merck
Consulting or Advisory Role - Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Exelixis; Fathom Biotechnology; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; Oncolys BioPharma; Pfizer; Pneuma Respiratory; Pyxis; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Sachet A. Shukla
Stock and Other Ownership Interests - Agenus; Agios; BreakBio Corp.; Bristol-Myers Squibb; Newlink Genetics
Patents, Royalties, Other Intellectual Property - Dana Farber Cancer Hospital
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI